65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com
Sector(s):
Industry:
Full-time employees: 5,325
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. David Loew | MD, CEO & Director | 41.53M | N/A | 1967 |
Mr. Aymeric Le Chatelier | Executive VP & CFO | 14.37M | N/A | 1969 |
Dr. Aidan Murphy Ph.D. | Executive VP and Head of Technical Operations | N/A | N/A | 1966 |
Mr. Craig Marks | Vice-President of Investor Relations | N/A | N/A | N/A |
Mr. Francois Garnier | Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer | N/A | N/A | 1962 |
Ms. Gwenan White | Executive VP and Head of Communications, Public Affairs & Sustainability | N/A | N/A | N/A |
Mr. Regis Mulot | Executive VP & Chief Human Resources Officer | N/A | N/A | 1966 |
Ms. Dominique Bery | Head of Nordics & Baltics | N/A | N/A | 1971 |
Mr. Bartosz Bednarz D.D.S. | Executive VP and Head of Global Product & Portfolio Strategy | N/A | N/A | N/A |
Mr. Philippe Lopes-Fernandes CBO | Executive VP & Chief Business Officer | N/A | N/A | N/A |
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Ipsen S.A.’s ISS governance QualityScore as of 1 July 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 7; Compensation: 7.